Cooper Companies: A Broken Quarter, an Activist Knocking, and 48 Hours Until Truth Time

Here's a stock that's basically holding its breath. Cooper Companies (COO) closed at $69.59, sitting near its 52-week low, down roughly 15% year-to-date, and now staring down a Q3 earnings print due Wednesday after the bell. Consensus wants $1.12 a share. The market wants a reason to stop flinching. Whether it gets one is genuinely a coin flip — and I mean that literally, not as a hedge-your-bets columnist tic.

Let's start with the ugly part, because it's ugly. Q2 FY26 delivered a $77.9 million net loss and a negative 2.87% operating margin — a stunning reversal from a 20.8% operating margin just one quarter prior. That's not a slow bleed, that's a cliff. Gross margins held fine around 68%, so whatever hit the P&L happened below the line — likely a charge or impairment — but the optics are brutal regardless: trailing EPS of $1.18 leaves the stock trading at a nosebleed ~59x trailing earnings. Yet the forward P/E sits at a much saner 13.9x, which only works if EPS snaps back to roughly $5. That's the whole bet, right there. Wednesday's print either starts validating that recovery story or it doesn't, and there isn't much room for "kind of."

Here's the part that keeps this from being a straightforward "sell the broken quarter" story: cash generation hasn't missed a beat. TTM operating cash flow of $953 million and free cash flow of $424 million are the kind of numbers that let a company service $2.46 billion in debt without breaking a sweat, even with a thin cash cushion of $138.8 million. Net debt/EBITDA runs around 2.6x — manageable, not alarming. Revenue is still growing too, up 6.1% year-over-year on a trailing basis. So this isn't a company falling apart. It's a company where the income statement had a very bad quarter while the cash engine kept humming. Markets tend to punish that combination first and ask questions later.

Then there's Jana Partners, rattling the cage. The activist has been pushing Cooper toward "strategic alternatives" — most notably floating a contact-lens-unit tie-up with Bausch + Lomb, and separately, chatter (via a Seeking Alpha piece) about a possible CooperSurgical divestiture. Either move would be a genuine re-rating catalyst, because a sum-of-the-parts breakup unlocks value the market clearly isn't pricing in right now — CooperSurgical's fertility franchise in particular carries premium multiples in a standalone or acquired context that get buried inside a conglomerate discount. This is the actual reason to stay interested in COO beyond the earnings coin flip: there's a credible path to value creation that has nothing to do with Wednesday's number.

Naturally, the analyst community can't agree on anything, which tells you something too. One shop has Cooper at a flat-out Hold. Another calls it a Moderate Buy. Price targets are scattered across an $81 to $92 range depending on which snapshot you grab — a $16-plus spread on a $70 stock is not "minor rounding," that's disagreement dressed up as precision. When the Street can't converge on a rating, that's usually a sign the story is genuinely unresolved, not that someone's model is broken.

Technically, the tape is doing exactly what you'd expect from a stock this confused: RSI near 37, price stacked below its 20/50/200-day averages, oscillating in a tight $69–$71 band. That's compression, and compression eventually resolves — usually violently. Support sits at $68, then $65, with the 52-week low of $58.89 as the last line before real trouble. Resistance is $73, then the $82–84 zone where the activist-premium crowd lives.

My take: this is not a stock to chase into an earnings print with a busted margin trend and a model that's already been beaten by a naive baseline on its own directional accuracy. But it's also not a stock to write off. The cash flow is real, the activist thesis is real, and the valuation gap between "broken conglomerate" and "unlocked sum of parts" is wide enough to matter. Watch Wednesday's print for margin stabilization, not just the EPS beat-or-miss headline. If operating margin snaps back toward double digits, the $81–92 targets start looking like the floor, not the ceiling. If it doesn't, $58.89 stops being a hypothetical.

Sit on your hands until Thursday morning. This one's going to tell you exactly what it is.